CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH In this Q&A with Dr. Jorge Cortes, the Director of the Georgia Cancer Center, the drug asciminib is discussed based on its utility as a third-generation TKI as well as its favorable, unique characteristics. Early data has shown promising results with few adverse events, possibly illuminating the drug as a potential first-in-class agent.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
